Cynvenio is proud to support cancer patients and their families with highly accurate and affordable cancer testing. Read what they’re saying about us.
“The women I know with Triple Negative Breast Cancer (TNBC) are scared by the statistics and what we see happen to others in our group. Many are “waiting for the other shoe to drop.” Some have safely made it past 3 and 5 years post-diagnosis without recurrence, others have not. Further still, there are others who are no longer with us as a result of their recurrence and metastases.
I joined the Cynvenio trial with the hope of benefitting myself and anyone diagnosed with TNBC in the future. It is encouraging to see this work being done and I am excited to participate. As a seeker of information, I see the potential of the NK VUE and LiquidBiopsy to identify circulating tumor cells in my body as a benefit and it gives me a bit of comfort that I’m being monitored in this way.”
“Being a cancer patient at Cedars-Sinai Medical Center with their top researchers, doctors and surgeons has saved my life. As I continue to reclaim my health being a participant in Cynvenio’s, “ClearID & NK Vue Testing” pilot surveillance study is an incredible bonus to the already extraordinary care I have going through, and now recovering from Triple Negative breast cancer. To have so many good eyes looking at my progress gives me confidence in my full recovery.”
– Cat Gwynn
Los Feliz, CA
“ClearID has meant so much to me and is continuing to provide comfort when it comes to me thinking about my care and well being Even if a mutation was found, I know that ClearID would find out through their testing so I could take on whatever it is right away.”
– Katie Burns
Los Osos, CA
“I was diagnosed with Invasive Ductal Cancer in November 2013. After genetic testing, I was informed that I am positive for the BRCA2 gene mutation. I was very fortunate that my breast cancer was found very early and was not aggressive. I have always felt that I got breast cancer so that I could help other women. I am participating in the Cynvenio TNBC Clinical Trial with the hope that the new liquid biopsy technology will help many women.”
– Sherri Rosenthal
Agoura Hills, CA